Investment supports development of innovative treatments designed to address the underlying causes of polycystic kidney disease
(NEW YORK CITY, NY – November 16, 2026) – The National Kidney Foundation (NKF) today highlighted its Innovation Fund investment in Estuary Biotherapeutics, a biotechnology company developing gene therapies designed to address the underlying causes of kidney disease.
The NKF Innovation Fund participated in Estuary's $93 million Series A financing, part of the $103 million in total funding the company announced in October. The funding will support development of new therapies for autosomal dominant polycystic kidney disease (ADPKD), the most common inherited kidney disease, and further advancement of the company's kidney-targeting technology.
ADPKD causes fluid-filled cysts to develop and grow in the kidneys, progressively damaging healthy kidney tissue. Over time, the disease can lead to kidney failure, requiring dialysis or a kidney transplant. Current treatments can slow disease progression, but there is no cure.
Estuary is developing gene therapies designed to go beyond slowing kidney disease by addressing its underlying genetic causes. The company's two lead programs target mutations in the PKD1 and PKD2 genes, which account for more than 90% of ADPKD cases. Building on research from Yale School of Medicine, Estuary hopes to develop treatments that could halt or potentially reverse the progression of the disease.
“Too many people living with kidney disease face a future of managing their condition rather than treating its underlying cause,” said Kevin Longino, Chief Investment Officer of the National Kidney Foundation and a kidney transplant recipient. “Estuary's work represents the kind of innovation we want to accelerate through the NKF Innovation Fund. By investing in promising technologies that could fundamentally change how kidney disease is treated, we're helping advance the possibility of better outcomes, longer lives, and ultimately a future without kidney disease.”
Estuary's initial programs focus on ADPKD, but the company plans to expand its technology to address other inherited and common kidney diseases. Its lead programs are expected to enter clinical trials in 2027 and 2028.
Launched in 2021, the NKF Innovation Fund works to accelerate funding, development, and commercialization of therapies that kidney patients need and deserve. The fund invests in early to mid-stage companies that are developing innovative, patient-centric kidney therapies. The long-term goals of the NKF Innovation Fund are to prevent kidney disease, eliminate the transplant waitlist, and provide better, safer treatments for dialysis patients so they can live fuller and more productive lives. For more information, visit kidney.org/innovationfund.
About the National Kidney Foundation
The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis and transplantation. For more information about NKF, visit kidney.org.
For Media Inquiries:
Jade Rivera-McFarlin
413-537-1155
jade.riveramcfarlin@kidney.org